DXS International (AQSE:DXSP) ROE % Adjusted to Book Value: -6.26% (As of Apr. 2025)


What is DXS International ROE % Adjusted to Book Value?

DXS International AQSE:DXSP ROE % Adjusted to Book Value is -6.26% as of Apr. 2025. The stock has 2 warning signs investors should review.

DXS International's ROE % for the quarter that ended in Apr. 2025 was -23.49%. DXS International's PB Ratio for the quarter that ended in Apr. 2025 was 3.75. DXS International's ROE % Adjusted to Book Value for the quarter that ended in Apr. 2025 was -6.26%.

DXS International ROE % Adjusted to Book Value Related Terms

DXS International ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for DXS International's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DXS International ROE % Adjusted to Book Value Chart

DXS International Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.14 4.08 10.70 -97.50 -6.26

DXS International Semi-Annual Data
Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 12.14 4.08 10.70 -97.50 -6.26

AQSE:DXSP vs VEEV, BTSG, TEM: ROE % Adjusted to Book Value Comparison

For the Health Information Services subindustry, DXS International's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DXS International ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DXS International's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where DXS International's ROE % Adjusted to Book Value falls into.


DXS International ROE % Adjusted to Book Value Calculation

DXS International's ROE % Adjusted to Book Value for the fiscal year that ended in Apr. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-23.49% / 3.75
=-6.26%

DXS International's ROE % Adjusted to Book Value for the quarter that ended in Apr. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-23.49% / 3.75
=-6.26%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -6.26% mean?
DXS International (AQSE:DXSP) has a ROE % Adjusted to Book Value of -6.26% as of Apr. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on DXS International and its competitors.
Is DXS International's ROE % Adjusted to Book Value too high?
DXS International's current ROE % Adjusted to Book Value is -6.26%.
How does DXS International's ROE % Adjusted to Book Value compare to VEEV and BTSG?
DXS International's ROE % Adjusted to Book Value of -6.26% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on DXS International and its competitors. DXS International's current ROE % Adjusted to Book Value is -6.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
Based on GuruFocus' analysis, DXS International (AQSE:DXSP) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.01 — trading 37.5% below its estimated fair value. The current ROE % Adjusted to Book Value is -6.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For DXS International (AQSE:DXSP), the current ROE % Adjusted to Book Value is -6.26% as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DXS International Business Description

Address 119 Saint Mary’s Road, Market Harborough, London, Leicestershire, GBR, LE16 7DT
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.